More intensive chemo ups survival in ewing sarcoma

October 29, 2012

(HealthDay)—More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of Clinical Oncology.

Richard B. Womer, M.D., from the Children's Hospital of Philadelphia, and colleagues conducted a prospective trial in which 568 patients younger than 50 years old with newly diagnosed localized extradural Ewing sarcoma were randomized to receive standard or intensified treatment with chemotherapy cycles beginning every 21 and 14 days, respectively (284 patients in each group). Patients received vincristine, , and alternating with ifosfamide and etoposide for 14 cycles, with filgrastim between cycles. At week 13, following four cycles in the standard arm and six cycles in the intensified arm, primary tumor treatment (surgery, radiation, or both) began.

The researchers found that, at a median of five years, event-free survival was 65 percent in the standard arm and 73 percent in the intensified arm (P = 0.048). Toxicity was similar between the groups.

"For localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than administered every three weeks, with no increase in toxicity," the authors write.

Explore further: More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

November 24, 2011
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years ...

Adding bavituximab to second-line chemotherapy doubles response rate

September 6, 2012
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012
(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

No benefit of induction chemo, high-dose boost in anal cancer

April 26, 2012
(HealthDay) -- Neither induction chemotherapy (ICT) nor high-dose radiation boost is associated with an improvement in five-year colostomy-free survival (CFS) in patients with locally advanced anal canal carcinoma (LAACC), ...

Recommended for you

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.